What it sells
Bio-new-drug developer with the ArkGen Multi-Body (AMB) multi-target antibody platform, a personalized neoantigen cancer vaccine, an LGR4 bone-disease therapeutic and TheraVac for osteopenia.
Business model breakdown
Workflow: what inputs become what output?
Develops protein-based biologic new drugs from a multi-target antibody platform through preclinical/clinical stages (immuno-oncology focus).
Economics: what it saves and how it charges
UnverifiedPre-revenue clinical/preclinical biotech; value from pipeline out-licensing or development (not stated).
Distribution: how it reaches customers
UnverifiedContact-led (phone/email); no commercial product, partnering via contact page.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-13 | Series A | KRW 10B | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.